HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CAN 508

has antiangiogenic activity; structure in first source

Also Known As:

CAN-508; CAN508

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Azo Compounds: 333
  - CAN 508: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - CAN 508: 3

Experts

1.	Ajani, Jaffer A: 1 article (04/2017)
2.	Chatterjee, Devkumar: 1 article (04/2017)
3.	Deng, Defeng: 1 article (04/2017)
4.	Guha, Sushovan: 1 article (04/2017)
5.	Hofstetter, Wayne: 1 article (04/2017)
6.	Kopetz, Scott: 1 article (04/2017)
7.	Krishnan, Sunil: 1 article (04/2017)
8.	Lin, Steven: 1 article (04/2017)
9.	Maru, Dipen: 1 article (04/2017)
10.	Mejia, Alicia: 1 article (04/2017)

Related Diseases

1.

Neoplasms (Cancer)

11/02/2006 - "The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. "
04/25/2017 - "In xenograft models, CAN508 (60 mg/kg/dayx10 days) and Flavopiridol (4mg/kg/dayx10 days) caused 50.8% and 63.1% reduction in xenograft tumors as compared to control on post-treatment day 21. "
09/01/2011 - "Moreover, CAN508 reduces expression of vascular endothelial growth factor by several human cancer cell lines. "

Related Drugs and Biologics

1.	Phenol (Carbolic Acid)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	alvocidib (flavopiridol)